Multiple endocrine neoplasia.
MEN1 and MEN2 are autosomal dominant cancer syndromes with the potential for considerable morbidity and mortality. Better understanding of the molecular pathogenesis in MEN1 and MEN2 has fostered the development of specific DNA screening. Knowing the genetic status of patients is valuable for making decisions regarding surveillance and interventions, such as prophylactic thyroidectomy for medullary thyroid cancer. Identifying new RET pathways has provided molecular targets for therapies that currently are being tested in clinical trials for locally advanced, metastatic, and recurrent medullary thyroid cancer.
White
Matthew L
ML
Department of Surgery, University of Michigan, and Department of Surgery, St. Joseph Mercy Hospital, 5301 McAuley Drive, Ann Arbor, MI 48197, USA.
Doherty
Gerard M
GM
D000970:Antineoplastic Agents / Q000627:therapeutic use; D004273:DNA, Neoplasm / Q000032:analysis; D005820:Genetic Testing; D006801:Humans; D008967:Molecular Biology; D018761:Multiple Endocrine Neoplasia Type 1 / Q000175:diagnosis* / Q000188:drug therapy / Q000235:genetics* / Q000601:surgery; D018813:Multiple Endocrine Neoplasia Type 2a / Q000175:diagnosis* / Q000188:drug therapy / Q000235:genetics* / Q000601:surgery; D011159:Population Surveillance
D000970:Antineoplastic Agents; D004273:DNA, Neoplasm